ERBB3 and neoplasm: In concordance with these claims, HER3/HER4 inhibition with an NRG1-targeted monoclonal antibody has been found to inhibit primary tumor growth and enhance the magnitude and duration of chemotherapy response in preclinical models, and to prevent disease relapse171.